NVCT Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 30.52%

Insider Buying (Last 12 Months): $3,041,799.02

Insider Selling (Last 12 Months): $0.00

Nuvectis Pharma Insider Trading History Chart

Nuvectis Pharma Share Price & Price History

^$6.74

▲ +0.36 (5.64%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Nuvectis Pharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/5/2025	Juan Sanchez	Director	Buy	13,000	$5.79	$75,270.00	78,150
11/5/2025	Matthew L Kaplan	Director	Buy	11,000	$5.84	$64,240.00	124,760
11/5/2025	Ron Bentsur	CEO	Buy	5,000	$5.72	$28,600.00	3,525,924
10/27/2025	Marlio Charles Mosseri	Major Shareholder	Buy	72,836	$6.28	$457,410.08	3,136,576
10/24/2025	Marlio Charles Mosseri	Major Shareholder	Buy	35,034	$6.15	$215,459.10	3,063,740
10/23/2025	Marlio Charles Mosseri	Major Shareholder	Buy	46,900	$6.06	$284,214.00	3,028,706
6/20/2025	Marlio Charles Mosseri	Major Shareholder	Buy	5,603	$7.99	$44,767.97	2,981,806
6/18/2025	Marlio Charles Mosseri	Major Shareholder	Buy	28,043	$8.05	$225,746.15	2,976,203
6/17/2025	Marlio Charles Mosseri	Major Shareholder	Buy	5,399	$8.11	$43,785.89	2,948,160
5/12/2025	Marlio Charles Mosseri	Major Shareholder	Buy	21,167	$8.11	$171,664.37	2,942,761
5/8/2025	Marlio Charles Mosseri	Major Shareholder	Buy	2,650	$8.65	$22,922.50	2,911,532
5/6/2025	Marlio Charles Mosseri	Major Shareholder	Buy	12,444	$8.59	$106,893.96	2,896,565
2/7/2025	Marlio Charles Mosseri	Major Shareholder	Buy	240,000	$5.00	$1,200,000.00	2,884,121
12/24/2024	Ron Bentsur	CEO	Buy	4,500	$4.65	$20,925.00	3,270,924
12/13/2024	Marlio Charles Mosseri	Major Shareholder	Buy	17,000	$4.70	$79,900.00	2,612,000
11/19/2024	Enrique Poradosu	Insider	Buy	2,000	$4.99	$9,980.00	1,506,319
11/15/2024	Ron Bentsur	CEO	Buy	20,000	$4.92	$98,400.00	3,266,424
5/14/2024	Ron Bentsur	CEO	Buy	1,940	$6.74	$13,075.60	3,246,424
5/10/2024	Enrique Poradosu	Insider	Buy	500	$6.29	$3,145.00	1,504,319
5/10/2024	Ron Bentsur	CEO	Buy	2,000	$6.40	$12,800.00	3,244,484
3/18/2024	Ron Bentsur	CEO	Buy	5,000	$10.29	$51,450.00	3,242,484
10/9/2023	Ron Bentsur	CEO	Buy	830	$11.19	$9,287.70	3,236,844
10/6/2023	Ron Bentsur	CEO	Buy	250	$11.27	$2,817.50	3,236,014
10/4/2023	Ron Bentsur	CEO	Buy	1,820	$10.95	$19,929.00	3,234,364
8/15/2023	Ron Bentsur	CEO	Buy	235	$14.34	$3,369.90	3,232,429
8/11/2023	Ron Bentsur	CEO	Buy	180	$14.66	$2,638.80	3,232,194
8/8/2023	Ron Bentsur	CEO	Buy	120	$14.83	$1,779.60	3,232,014
7/31/2023	Marlio Charles Mosseri	Major Shareholder	Buy	860	$13.88	$11,936.80	2,595,000
7/28/2023	Marlio Charles Mosseri	Major Shareholder	Buy	2,584	$13.91	$35,943.44	2,594,140
7/26/2023	Marlio Charles Mosseri	Major Shareholder	Buy	10,000	$13.97	$139,700.00	2,590,000
7/21/2023	Ron Bentsur	CEO	Buy	225	$14.85	$3,341.25	3,231,894
7/20/2023	Marlio Charles Mosseri	Major Shareholder	Buy	5,394	$14.40	$77,673.60	2,577,156
7/19/2023	Ron Bentsur	CEO	Buy	200	$14.33	$2,866.00	3,231,559
7/18/2023	Marlio Charles Mosseri	Major Shareholder	Buy	9,149	$14.84	$135,771.16	2,563,762
7/14/2023	Ron Bentsur	CEO	Buy	150	$15.03	$2,254.50	3,231,359
7/11/2023	Marlio Charles Mosseri	Major Shareholder	Buy	10,000	$15.36	$153,600.00	2,551,328
7/7/2023	Marlio Charles Mosseri	Major Shareholder	Buy	8,948	$15.19	$135,920.12	2,541,328
7/6/2023	Ron Bentsur	CEO	Buy	320	$14.88	$4,761.60	3,231,099
7/5/2023	Marlio Charles Mosseri	Major Shareholder	Buy	1,176	$15.52	$18,251.52	2,529,201
6/26/2023	Marlio Charles Mosseri	Major Shareholder	Buy	16,760	$16.46	$275,869.60	2,528,025
6/26/2023	Ron Bentsur	CEO	Buy	750	$16.50	$12,375.00	3,230,779
6/23/2023	Marlio Charles Mosseri	Major Shareholder	Buy	73,175	$17.43	$1,275,440.25	2,511,265
6/21/2023	Marlio Charles Mosseri	Major Shareholder	Buy	6,091	$17.71	$107,871.61	2,431,091
6/21/2023	Ron Bentsur	CEO	Buy	500	$17.88	$8,940.00	3,230,029
6/15/2023	Marlio Charles Mosseri	Major Shareholder	Buy	32,124	$17.71	$568,916.04	2,412,300
6/7/2023	Ron Bentsur	CEO	Buy	230	$17.41	$4,004.30	3,229,409
5/31/2023	Ron Bentsur	CEO	Buy	330	$17.28	$5,702.40	3,229,179
5/24/2023	Ron Bentsur	CEO	Buy	200	$17.49	$3,498.00	3,228,849
5/16/2023	Ron Bentsur	CEO	Buy	320	$17.02	$5,446.40	3,228,649
3/27/2023	Enrique Poradosu	Insider	Buy	500	$11.55	$5,775.00	1,373,819
3/23/2023	Ron Bentsur	CEO	Buy	230	$12.13	$2,789.90	3,228,329
3/21/2023	Ron Bentsur	CEO	Buy	480	$12.08	$5,798.40	3,228,099
3/21/2023	Shay Shemesh	Insider	Buy	420	$11.99	$5,035.80	1,361,955
3/15/2023	Shay Shemesh	Insider	Buy	670	$10.71	$7,175.70	1,361,535
3/14/2023	Ron Bentsur	CEO	Buy	1,680	$10.85	$18,228.00	3,227,139
12/21/2022	Shay Shemesh	Insider	Buy	500	$7.65	$3,825.00	1,245,865

SEC Filings (Institutional Ownership Changes) for Nuvectis Pharma (NASDAQ:NVCT)

96.77% of Nuvectis Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Nuvectis Pharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/10/2025	Avalon Trust Co	10,000	$60K	0.0%	N/A	0.039%
11/7/2025	GSA Capital Partners LLP	23,450	$0.14M	0.0%	-40.1%	0.092%
11/7/2025	Vanguard Group Inc.	698,708	$4.21M	0.0%	+4.8%	2.728%
11/3/2025	New York State Common Retirement Fund	5,000	$30K	0.0%	-61.5%	0.020%
10/24/2025	Iridian Asset Management LLC CT	405,621	$2.44M	1.0%	+8.8%	1.593%
8/19/2025	Marex Group plc	15,000	$0.11M	0.0%	N/A	0.059%
8/15/2025	Bank of America Corp DE	8,565	$64K	0.0%	+417.2%	0.034%
8/14/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	7,029	$53K	0.0%	N/A	0.028%
8/13/2025	Marshall Wace LLP	63,613	$0.48M	0.0%	+63.6%	0.250%
8/13/2025	New York State Common Retirement Fund	13,000	$97K	0.0%	N/A	0.051%
8/12/2025	JPMorgan Chase & Co.	6,263	$47K	0.0%	+3,398.9%	0.025%
8/8/2025	Police & Firemen s Retirement System of New Jersey	3,785	$28K	0.0%	N/A	0.018%
8/8/2025	Austin Wealth Management LLC	20,125	$0.14M	0.0%	-50.0%	0.096%
8/8/2025	Geode Capital Management LLC	285,332	$2.13M	0.0%	+110.8%	1.366%
7/24/2025	Baldwin Wealth Partners LLC MA	350,461	$2.62M	0.2%	-2.2%	1.678%
6/27/2025	Goldman Sachs Group Inc.	45,608	$0.45M	0.0%	N/A	0.218%
5/19/2025	Jane Street Group LLC	42,299	$0.41M	0.0%	N/A	0.202%
5/16/2025	Goldman Sachs Group Inc.	45,608	$0.45M	0.0%	N/A	0.218%
5/15/2025	OMERS ADMINISTRATION Corp	32,882	$0.32M	0.0%	N/A	0.139%
5/1/2025	Austin Wealth Management LLC	40,250	$0.39M	0.1%	N/A	0.172%
4/30/2025	Iridian Asset Management LLC CT	253,972	$2.48M	0.8%	N/A	1.086%
4/23/2025	Oppenheimer & Co. Inc.	41,000	$0.40M	0.0%	+64.0%	0.175%
4/14/2025	Baldwin Wealth Partners LLC MA	358,461	$3.50M	0.2%	+0.7%	1.532%
4/11/2025	Blue Zone Wealth Advisors LLC	10,424	$0.10M	0.0%	N/A	0.045%
2/17/2025	Squarepoint Ops LLC	19,071	$0.10M	0.0%	N/A	0.099%
2/17/2025	Two Sigma Investments LP	18,570	$100K	0.0%	-30.7%	0.096%
2/17/2025	Millennium Management LLC	29,698	$0.16M	0.0%	-56.6%	0.154%
2/17/2025	Cubist Systematic Strategies LLC	6,294	$34K	0.0%	N/A	0.033%
2/14/2025	Northern Trust Corp	25,725	$0.14M	0.0%	+68.7%	0.133%
2/13/2025	Marshall Wace LLP	124,571	$0.67M	0.0%	+191.0%	0.645%
2/12/2025	Edmond DE Rothschild Holding S.A.	15,170	$82K	0.0%	-20.9%	0.079%
2/12/2025	Baxter Bros Inc.	15,000	$81K	0.0%	+20.0%	0.078%
2/5/2025	Oppenheimer & Co. Inc.	25,000	$0.14M	0.0%	N/A	0.129%
1/30/2025	Nations Financial Group Inc. IA ADV	13,500	$73K	0.0%	+35.0%	0.070%
1/28/2025	Forbes J M & Co. LLP	59,000	$0.32M	0.0%	+21.9%	0.305%
1/22/2025	Baldwin Wealth Partners LLC MA	355,961	$1.93M	0.1%	+104.4%	1.842%
11/16/2024	Geode Capital Management LLC	79,716	$0.50M	0.0%	+49.8%	0.413%
11/5/2024	GSA Capital Partners LLP	50,129	$0.32M	0.0%	+3.7%	0.269%
11/5/2024	Nations Financial Group Inc. IA ADV	10,000	$63K	0.0%	N/A	0.054%
10/25/2024	Iridian Asset Management LLC CT	55,380	$0.35M	0.1%	N/A	0.297%
9/16/2024	Point72 Asia Singapore Pte. Ltd.	9,203	$58K	0.0%	N/A	0.050%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	9,203	$58K	0.0%	N/A	0.050%
8/14/2024	Marshall Wace LLP	33,868	$0.21M	0.0%	-32.4%	0.185%
8/9/2024	Renaissance Technologies LLC	74,500	$0.47M	0.0%	+20.7%	0.406%
7/16/2024	Baxter Bros Inc.	12,500	$79K	0.0%	N/A	0.068%
7/12/2024	Baldwin Brothers LLC MA	168,630	$1.07M	0.1%	+9.4%	0.918%
5/10/2024	Vanguard Group Inc.	298,800	$2.45M	0.0%	+1.5%	1.626%
4/18/2024	Blue Zone Wealth Advisors LLC	14,350	$0.12M	0.0%	N/A	0.081%
2/12/2024	Edmond DE Rothschild Holding S.A.	19,170	$0.16M	0.0%	N/A	0.111%
1/30/2024	Strs Ohio	6,200	$51K	0.0%	+59.0%	0.036%
1/8/2024	Baldwin Brothers LLC MA	142,040	$1.19M	0.1%	+22.0%	0.820%
11/2/2023	Forbes J M & Co. LLP	34,000	$0.44M	0.1%	-49.3%	0.197%
10/26/2023	Strs Ohio	3,900	$50K	0.0%	+178.6%	0.023%
10/10/2023	Baldwin Brothers LLC MA	116,380	$1.50M	0.1%	+29.2%	0.675%
8/10/2023	Hollencrest Capital Management	3,040	$49K	0.0%	N/A	0.019%
8/4/2023	American International Group Inc.	3,298	$53K	0.0%	N/A	0.021%
8/3/2023	Forbes J M & Co. LLP	67,000	$1.07M	0.1%	N/A	0.418%
8/2/2023	Bank of Montreal Can	11,012	$0.20M	0.0%	N/A	0.069%
7/14/2023	Baldwin Brothers LLC MA	90,061	$1.44M	0.1%	-37.4%	0.563%
5/11/2023	Edmond DE Rothschild Holding S.A.	24,570	$0.32M	0.0%	N/A	0.167%
4/21/2023	Baldwin Brothers LLC MA	143,800	$1.89M	0.2%	+7.9%	0.975%
11/4/2022	Ronit Capital LLP	562,547	$3.99M	5.4%	+34.2%	3.843%
10/14/2022	Baldwin Brothers LLC MA	133,000	$0.94M	0.1%	+9.9%	0.908%
8/4/2022	Ronit Capital LLP	419,282	$4.70M	6.7%	-23.8%	3.297%
7/18/2022	Baldwin Brothers LLC MA	121,000	$1.36M	0.2%	N/A	0.951%
5/11/2022	Ronit Capital LLP	550,000	$4.08M	5.1%	N/A	4.325%

Data available starting January 2016

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Today's Range

Now: $6.74

$6.39

$6.79

50 Day Range

MA: $6.11

$5.65

$6.77

52 Week Range

Now: $6.74

$4.44

$11.52

Volume

131,799 shs

Average Volume

80,701 shs

Market Capitalization

$172.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Nuvectis Pharma?: Nuvectis Pharma's top insider investors include:
Ron Bentsur (CEO)
Marlio Charles Mosseri (Major Shareholder)
Enrique Poradosu (Insider)
Matthew L Kaplan (Director)
Juan Sanchez (Director)
Learn More about top insider investors at Nuvectis Pharma.
Who are the major institutional investors of Nuvectis Pharma?: Nuvectis Pharma's top institutional shareholders include:
Vanguard Group Inc. — 2.73%
Iridian Asset Management LLC CT — 1.59%
GSA Capital Partners LLP — 0.09%
Avalon Trust Co — 0.04%
New York State Common Retirement Fund — 0.02%
Learn More about top institutional investors of Nuvectis Pharma stock.
Which major investors are selling Nuvectis Pharma stock?: In the previous quarter, NVCT stock was sold by these institutional investors:
GSA Capital Partners LLP
New York State Common Retirement Fund
Which major investors are buying Nuvectis Pharma stock?: In the last quarter, NVCT stock was purchased by institutional investors including:
Iridian Asset Management LLC CT
Vanguard Group Inc.
Avalon Trust Co
Within the last year, these company insiders have bought Nuvectis Pharma stock:
Ron Bentsur (CEO)
Marlio Charles Mosseri (Major Shareholder)
Enrique Poradosu (Insider)
Matthew L Kaplan (Director)
Juan Sanchez (Director)
Learn More investors buying Nuvectis Pharma stock.